Skip to main content
    • Aa
    • Aa

Novel therapeutic strategies for the treatment of protein-misfolding diseases

  • Jean-Christophe Rochet (a1)

Most proteins in the cell adopt a compact, globular fold that determines their stability and function. Partial protein unfolding under conditions of cellular stress results in the exposure of hydrophobic regions normally buried in the interior of the native structure. Interactions involving the exposed hydrophobic surfaces of misfolded protein conformers lead to the formation of toxic aggregates, including oligomers, protofibrils and amyloid fibrils. A significant number of human disorders (e.g. Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis and type II diabetes) are characterised by protein misfolding and aggregation. Over the past five years, outstanding progress has been made in the development of therapeutic strategies targeting these diseases. Three promising approaches include: (1) inhibiting protein aggregation with peptides or small molecules identified via structure-based drug design or high-throughput screening; (2) interfering with post-translational modifications that stimulate protein misfolding and aggregation; and (3) upregulating molecular chaperones or aggregate-clearance mechanisms. Ultimately, drug combinations that capitalise on more than one therapeutic strategy will constitute the most effective treatment for patients with these devastating illnesses.

Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1C.M. Dobson (2003) Protein folding and misfolding. Nature 426, 884-890

2K.N. Dahlgren (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277, 32046-32053

3D.M. Walsh (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539

4S. Lesne (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357

5E. Cohen (2006) Opposing activities protect against age-onset proteotoxicity. Science 313, 1604-1610

6M. Arrasate (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810

7J.R. Silveira (2005) The most infectious prion protein particles. Nature 437, 257-261

8N. Reixach (2004) Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A 101, 2817-2822

9M.J. Volles (2001) Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819

10H.A. Lashuel (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291

11R. Kayed (2004) Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279, 46363-46366

12M. Hashimoto (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med 4, 21-36

13M.P. Mattson and M. Sherman (2003) Perturbed signal transduction in neurodegenerative disorders involving aberrant protein aggregation. Neuromolecular Med 4, 109-132

14A.C. Rego and L.P. de Almeida (2005) Molecular targets and therapeutic strategies in Huntington's disease. Curr Drug Targets CNS Neurol Disord 4, 361-381

15R. Nelson and D. Eisenberg (2006) Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol 16, 260-265

16J.C. Rochet and P.T. Lansbury Jr. (2000) Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 10, 60-68

17A.T. Petkova , W.M. Yau and R. Tycko (2006) Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry 45, 498-512

18A.T. Petkova (2005) Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 307, 262-265

19M. Torok (2002) Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem 277, 40810-40815

20A.D. Williams (2004) Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis. J Mol Biol 335, 833-842

21N.A. Whittemore (2005) Hydrogen-deuterium (H/D) exchange mapping of Abeta 1-40 amyloid fibril secondary structure using nuclear magnetic resonance spectroscopy. Biochemistry 44, 4434-4441

22I. Kheterpal (2006) Structural differences in Abeta amyloid protofibrils and fibrils mapped by hydrogen exchange–mass spectrometry with on-line proteolytic fragmentation. J Mol Biol 361, 785-795

23S. Shivaprasad and R. Wetzel (2006) Scanning cysteine mutagenesis analysis of Abeta-(1–40) amyloid fibrils. J Biol Chem 281, 993-1000

24T. Luhrs (2005) 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A 102, 17342-17347

25A. Der-Sarkissian (2003) Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling. J Biol Chem 278, 37530-37535

26C. Del Mar (2005) Structure and properties of alpha-synuclein and other amyloids determined at the amino acid level. Proc Natl Acad Sci U S A 102, 15477-15482

27H. Heise (2005) Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. Proc Natl Acad Sci U S A 102, 15871-15876

28O.S. Makin (2005) Molecular basis for amyloid fibril formation and stability. Proc Natl Acad Sci U S A 102, 315-320

29S. Sambashivan (2005) Amyloid-like fibrils of ribonuclease A with three-dimensional domain-swapped and native-like structure. Nature 437, 266-269

30K.L. Sciarretta (2006) Spatial separation of beta-sheet domains of beta-amyloid: disruption of each beta-sheet by N-methyl amino acids. Biochemistry 45, 9485-9495

31L.M. Yan (2006) Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc Natl Acad Sci U S A 103, 2046-2051

32K.L. Sciarretta , D.J. Gordon and S.C. Meredith (2006) Peptide-based inhibitors of amyloid assembly. Methods Enzymol 413, 273-312

33T. Sato (2006) Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry 45, 5503-5516

34K.A. Conway (2001) Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294, 1346-1349

35J.C. Rochet (2004) Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci 23, 23-34

36B.J. Blanchard (2004) Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc Natl Acad Sci U S A 101, 14326-14332

37W. Kim (2006) A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. ACS Chem Biol 1, 461-469

38C. Chirita , M. Necula and J. Kuret (2004) Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43, 2879-2887

39V. Heiser (2002) Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci U S A 99 Suppl 4, 16400-16406

40E. Hockly (2006) Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiol Dis 21, 228-236

41J. Wang (2005) Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci 6, 1

42X. Zhang (2005) A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A 102, 892-897

43U.A. Desai (2006) Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum Mol Genet 15, 2114-2124

44R.A. Bodner (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A 103, 4246-4251

45U. Bertsch (2005) Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. J Virol 79, 7785-7791

46D.A. Kocisko (2003) New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 77, 10288-10294

47D.A. Kocisko and B. Caughey (2006) Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo. J Virol 80, 1044-1046

48W. Colon and J.W. Kelly (1992) Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654-8660

49S.M. Johnson (2005) Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 38, 911-921

50D.C. Fry (2006) Protein-protein interactions as targets for small molecule drug discovery. Biopolymers 84, 535-552

51S.L. Adamski-Werner (2004) Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 47, 355-374

52P. Hammarstrom (2003) Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299, 713-716

53E. Morais-de-Sa (2004) The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. J Biol Chem 279, 53483-53490

54S.M. Johnson (2005) Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem 48, 1576-1587

55H.M. Petrassi (2005) Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. J Am Chem Soc 127, 6662-6671

56R.L. Wiseman , N.S. Green and J.W. Kelly (2005) Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. Biochemistry 44, 9265-9274

57N.S. Green , T.R. Foss and J.W. Kelly (2005) Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci U S A 102, 14545-14550

58M.A. Hough (2004) Dimer destabilization in superoxide dismutase may result in disease-causing properties: structures of motor neuron disease mutants. Proc Natl Acad Sci U S A 101, 5976-5981

59S.S. Ray (2005) Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc Natl Acad Sci U S A 102, 3639-3644

61C. De Jonghe (2001) Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet 10, 1665-1671

62M.S. Wolfe (2002) APP, Notch, and presenilin: molecular pieces in the puzzle of Alzheimer's disease. Int Immunopharmacol 2, 1919-1929

63T. Hamaguchi , K. Ono and M. Yamada (2006) Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. Cell Mol Life Sci 63, 1538-1552

64S. Weggen (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216

65D. Beher (2004) Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem 279, 43419-43426

66Y. Zhou (2003) Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302, 1215-1217

67L. Desire (2005) RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo. J Biol Chem 280, 37516-37525

68S. Manes (2003) From rafts to crafts: membrane asymmetry in moving cells. Trends Immunol 24, 320-326

69C.J. Phiel (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439

70W.J. Netzer (2003) Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A 100, 12444-12449

71P.C. Fraering (2005) gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem 280, 41987-41996

72J.D. Best (2007) The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 320, 552-558

73L. Hong (2000) Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290, 150-153

74D.C. Cole (2006) Acylguanidines as small-molecule beta-secretase inhibitors. J Med Chem 49, 6158-6161

75J.N. Freskos (2007) Design of potent inhibitors of human beta-secretase. Part 2. Bioorg Med Chem Lett 17, 78-81

76A.K. Ghosh (2006) Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (beta-secretase) inhibitors. J Am Chem Soc 128, 5310-5311

77S. Hanessian (2005) Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J Med Chem 48, 5175-5190

78S.J. Stachel (2006) Macrocyclic inhibitors of beta-secretase: functional activity in an animal model. J Med Chem 49, 6147-6150

79W.P. Chang (2004) In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J Neurochem 89, 1409-1416

80F.M. Laird (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25, 11693-11709

81X. Hu (2006) Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9, 1520-1525

82M. Willem (2006) Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314, 664-666

83C.A. Saura (2005) Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci 25, 6755-6764

84M. Sastre (2006) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 103, 443-448

85A.S. Espeseth (2005) Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics. J Biol Chem 280, 17792-17797

86M.A. Leissring (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093

87D.S. Choi (2006) PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci U S A 103, 8215-8220

88T. Saito (2005) Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 11, 434-439

89J. Gafni (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 279, 20211-20220

90R.K. Graham (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125, 1179-1191

91S.J. Berke (2004) Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem 89, 908-918

92A. Haacke (2006) Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. Hum Mol Genet 15, 555-568

93E. Cattaneo , C. Zuccato and M. Tartari (2005) Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 6, 919-930

94W. Li (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 102, 2162-2167

95C.W. Liu (2005) A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem 280, 22670-22678

96T.C. Gamblin (2003) Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100, 10032-10037

97H. Yin and J. Kuret (2006) C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett 580, 211-215

98L.J. Page (2005) Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. Embo J 24, 4124-4132

99F. Chen (2004) Posttranslational modifications of tau–role in human tauopathies and modeling in transgenic animals. Curr Drug Targets 5, 503-515

100A. Alonso (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A 98, 6923-6928

101K. Duff and E. Planel (2005) Untangling memory deficits. Nat Med 11, 826-827

102C.W. Wittmann (2001) Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711-714

103C. Andorfer (2005) Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25, 5446-5454

104K. Santacruz (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481

105S. Le Corre (2006) An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A 103, 9673-9678

106C. Alonso Adel (2006) Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci U S A 103, 8864-8869

108J. Avila (2006) Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett 580, 2922-2927

109J.J. Lucas (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. Embo J 20, 27-39

110G.R. Jackson (2002) Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34, 509-519

111J.C. Cruz (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483

112W. Noble (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565

113S.J. Liu (2004) Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem 279, 50078-50088

114S. Sato (2006) Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. J Neurochem 98, 1573-1584

115M. Hoshi (2003) Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A 100, 6370-6375

117W. Noble (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102, 6990-6995

118R. Bhat (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278, 45937-45945

120Y.L. Zheng (2005) A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. Embo J 24, 209-220

121F. Plattner , M. Angelo and K.P. Giese (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281, 25457-25465

123J.P. Anderson (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281, 29739-29752

124W.W. Smith (2005) alpha-Synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci 25, 5544-5552

125L. Chen and M.B. Feany (2005) alpha-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8, 657-663

126E.J. Kim (2006) Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. J Biol Chem 281, 33250-33257

127B.J. Tabner (2005) Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J Biol Chem 280, 35789-35792

128K.J. Barnham (2003) Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 278, 42959-42965

129D.A. Butterfield and D. Boyd-Kimball (2005) The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta 1703, 149-156

130L. Hou (2002) Methionine 35 oxidation reduces fibril assembly of the amyloid abeta-(1–42) peptide of Alzheimer's disease. J Biol Chem 277, 40173-40176

131M. Palmblad , A. Westlind-Danielsson and J. Bergquist (2002) Oxidation of methionine 35 attenuates formation of amyloid beta -peptide 1-40 oligomers. J Biol Chem 277, 19506-19510

132G. Bitan (2003) A molecular switch in amyloid assembly: Met35 and amyloid beta-protein oligomerization. J Am Chem Soc 125, 15359-15365

133Q. Zhang (2004) Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A 101, 4752-4757

134K. Ono (2003) Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 87, 172-181

135M. Masuda (2006) Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 45, 6085-6094

136F. Yang (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280, 5892-5901

137E. Matsubara (2003) Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 85, 1101-1108

138Z. Feng (2006) Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic Biol Med 40, 101-109

139H.M. Abdul (2006) Acetyl-l-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J Neurosci Res 84, 398-408

140C.W. Ritchie (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60, 1685-1691

141E.H. Norris (2003) Effects of oxidative and nitrative challenges on α-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 278, 27230-27240

142G. Yamin , V.N. Uversky and A.L. Fink (2003) Nitration inhibits fibrillation of human α-synuclein in vitro by formation of soluble oligomers. FEBS Lett 542, 147-152

143N.B. Cole (2005) Metal-catalyzed oxidation of alpha synuclein: helping to define the relationship between oligomers, protofilaments and filaments. J Biol Chem 280, 9678-9690

144C.B. Glaser (2005) Methionine oxidation, alpha-synuclein and Parkinson's disease. Biochim Biophys Acta 1703, 157-169

145H. Mirzaei (2006) Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry. Anal Chem 78, 2422-2431

146D.A. Bosco (2006) Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol 2, 249-253

147M. Zhu (2004) The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem 279, 26846-26857

148K. Ono and M. Yamada (2006) Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 97, 105-115

149F. Giorgini (2005) A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 37, 526-531

150A. Wyttenbach (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet 11, 1137-1151

151W.J. Firdaus (2006) Analysis of oxidative events induced by expanded polyglutamine huntingtin exon 1 that are differentially restored by expression of heat shock proteins or treatment with an antioxidant. Febs J 273, 3076-3093

152W.J. Firdaus (2006) Huntingtin inclusion bodies are iron-dependent centers of oxidative events. Febs J 273, 5428-5441

153D. Dias-Santagata (2007) Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J Clin Invest 117, 236-245

154H.X. Deng (2006) Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl Acad Sci U S A 103, 7142-7147

155P.J. Muchowski and J.L. Wacker (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6, 11-22

156A.M. Cuervo (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292-1295

157C.G. Evans , S. Wisen and J.E. Gestwicki (2006) Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem 281, 33182-33191

158M.M. Wilhelmus (2006) Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity. Brain Res 1089, 67-78

159J. Klucken (2004) Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem 279, 25497-25502

160Y. Zhou (2004) Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem 279, 39155-39164

161P.K. Auluck (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868

162M.M. Dedmon (2005) Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J Biol Chem 280, 14733-14740

163C. Huang (2006) Heat shock protein 70 inhibits alpha-synuclein fibril formation via interactions with diverse intermediates. J Mol Biol 364, 323-336

164A. Zourlidou , M.D. Payne Smith and D.S. Latchman (2004) HSP27 but not HSP70 has a potent protective effect against alpha-synuclein-induced cell death in mammalian neuronal cells. J Neurochem 88, 1439-1448

165T.F. Outeiro (2006) Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun 351, 631-638

166J.L. Wacker (2004) Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol 11, 1215-1222

167V.M. Miller (2005) CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci 25, 9152-9161

168N.R. Jana (2005) Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J Biol Chem 280, 11635-11640

169I. Al-Ramahi (2006) CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J Biol Chem 281, 26714-26724

170C. Behrends (2006) Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol Cell 23, 887-897

171A. Kitamura (2006) Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat Cell Biol 8, 1163-1170

172S. Tam (2006) The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol 8, 1155-1162

173J.E. Gestwicki , G.R. Crabtree and I.A. Graef (2004) Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation. Science 306, 865-869

175A.K. McCollum (2006) Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res 66, 10967-10975

176P.J. McLean (2004) Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun 321, 665-669

177P.K. Auluck , M.C. Meulener and N.M. Bonini (2005) Mechanisms of suppression of {alpha}-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem 280, 2873-2878

178D.G. Hay (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 13, 1389-1405

179H.Y. Shen (2005) Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 280, 39962-39969

180S. Ansar (2007) A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorg Med Chem Lett 17, 1984-1990

181S.D. Westerheide (2004) Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 279, 56053-56060

182J.A. Johnston , C.L. Ward and R.R. Kopito (1998) Aggresomes: a cellular response to misfolded proteins. J Cell Biol 143, 1883-1898

183A. Iwata (2005) HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 280, 40282-40292

184B. Ravikumar (2005) Dynein mutations impair autophagic clearance of aggregate-prone proteins. Nat Genet 37, 771-776

185H.J. Lee and S.J. Lee (2002) Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem 277, 48976-48983

186H.J. Lee (2004) Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 24, 1888-1896

187J.L. Webb (2003) alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278, 25009-25013

188M. Tanaka (2004) Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 279, 4625-4631

189S. Waelter (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 12, 1393-1407

190J.P. Taylor (2003) Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet 12, 749-757

191A. Iwata (2005) Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc Natl Acad Sci U S A 102, 13135-13140

192B. Ravikumar , R. Duden and D.C. Rubinsztein (2002) Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 11, 1107-1117

193D.C. Rubinsztein (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443, 780-786

194B. Ravikumar (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36, 585-595

195Z. Berger (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15, 433-442

196S. Vignot (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16, 525-537

197S. Sarkar (2005) Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 170, 1101-1111

198S. Sarkar (2007) Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and {alpha}-synuclein. J Biol Chem 282, 5641-5652

199V.M. Miller (2004) Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res 32, 661-668

200Y. Saito (2005) Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model. J Biol Chem 280, 42826-42830

201M.K. Sapru (2006) Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 198, 382-390

202A.A. Cooper (2006) alpha-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324-328

203H.F. Poon (2005) Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice–a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 39, 453-462

204E.A. Nollen (2004) Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci U S A 101, 6403-6408

205G. Morfini (2006) JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat Neurosci 9, 907-916

206J.W. Kelly (1996) Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 6, 11-17

207H.Y. Zoghbi and H.T. Orr (2000) Glutamine repeats and neurodegeneration. Annu Rev Neurosci 23, 217-247

208J.P. Taylor , J. Hardy and K.H. Fischbeck (2002) Toxic proteins in neurodegenerative disease. Science 296, 1991-1995

209B. Caughey and P.T. Lansbury (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26, 267-298

210C.A. Ross and M.A. Poirier (2004) Protein aggregation and neurodegenerative disease. Nat Med 10 Suppl, S10-17

211T.K. Chaudhuri and S. Paul (2006) Protein-misfolding diseases and chaperone-based therapeutic approaches. Febs J 273, 1331-1349

L.D. Estrada and C. Soto (2006) Inhibition of protein misfolding and aggregation by small rationally-designed peptides. Curr Pharm Des 12, 2557-2567

M. Herbst and E.E. Wanker (2006) Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation. Curr Pharm Des 12, 2543-2555

B.C. May , C. Govaerts and F.E. Cohen (2006) Developing therapeutics for the diseases of protein misfolding. Neurology 66, S118-122

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *